ArticleJournal of clinical & translational endocrinology2021
Body composition in individuals with cystic fibrosis.
Article in Journal of clinical & translational endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The role of ultrasound of the quadriceps femoris in people with cystic fibrosis: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026Pooled it
- Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2024Trial
- Body Composition Assessment in Pediatric Cystic Fibrosis in the Highly Effective Modulator Therapy Era-A Pilot Study.Nutrients · 2026Article
- Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis.Biology · 2026Review
- The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Effects of inspiratory muscle training on physical fitness in cystic fibrosis: a systematic review and meta-analysis.BMC sports science, medicine & rehabilitation · 2025Article
- Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis.The American journal of clinical nutrition · 2025Article
- Cardiometabolic insights in cystic fibrosis and highly effective modulator therapies: a narrative review.Endocrine connections · 2025Review
- Integrating Imaging and Nutrition: Chest CT Muscle Analysis in Adults with Cystic Fibrosis.Nutrients · 2025Article
- Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis.Pediatric pulmonology · 2025Article
- Evolution and Prognostic Variables of Cystic Fibrosis in Children and Young Adults: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis.Scientific reports · 2024Article
- Increased fat mass and obesity risk after elexacaftor-tezacaftor-ivacaftor therapy in young adults with cystic fibrosis.Frontiers in nutrition · 2024Article
- Predictors of frequency of CF care in the US Cystic Fibrosis Foundation Patient Registry.PloS one · 2024Observational
- Article
- Evolving Nutritional Needs in Cystic Fibrosis.Life (Basel, Switzerland) · 2023Review
- Article
- Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study.Pediatric pulmonology · 2023Article
- Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because nutritional status is intimately linked with pulmonary function and survival, nutrition has been at the mainstay of cystic fibrosis (CF) care. Body Mass Index (BMI) is traditionally used to define nutritional status because of the ease with which it can be calculated, but it has a number of limitations including its inability to differentiate fat mass (FM) from lean body mass (LBM), the latter thought to confer health advantage. A number of tools are available to quantify body composition including dual-energy x-ray absorptiometry (DXA), bioelectrical impedance, MRI, CT, air displacement plethysmography, and stable isotopes, and these have been used to varying degrees in studies of CF. In CF, LBM tends to be lower for a given BMI, particularly at lower BMI. In adults, lower fat-free mass (FFM) correlates with greater CF disease severity, lower pulmonary function and higher inflammatory markers. FFM is also positively associated with greater bone mineral density, while greater FM is associated with greater loss of lumbar spine bone mineral density over 2 years. In youth, LBM is positively associated with pulmonary function. The predictive value of body composition for functional and clinical outcomes and the role of improving LBM on these outcomes remain undefined. With improvements in BMI accompanying highly-effective modulator therapy, closer evaluations of body composition may inform risk for more traditional, non-CF adult outcomes in CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.